Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Celon Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Celon Pharma şirketinin toplam hissedar öz sermayesi PLN459.4M ve toplam borcu PLN0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla PLN576.3M ve PLN117.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

zł0

Borç

Faiz karşılama oranı	n/a
Nakit	zł121.09m
Eşitlik	zł459.37m
Toplam yükümlülükler	zł116.96m
Toplam varlıklar	zł576.33m

Son finansal sağlık güncellemeleri

Recent updates

A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price

Aug 21

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Sep 24

Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans

Jul 13

We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow

Nov 04

We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth

Aug 04

Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly

May 23

Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)

Mar 02

Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Feb 09

Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?

Jan 20

Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain

Dec 24

Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Dec 03

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CLN 'nin kısa vadeli varlıkları ( PLN206.7M ) kısa vadeli yükümlülüklerini ( PLN79.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: CLN şirketinin kısa vadeli varlıkları ( PLN206.7M ) uzun vadeli yükümlülüklerini ( PLN37.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CLN borçsuzdur.

Borcun Azaltılması: CLN un 5 yıl önce borcu yoktu.

Borç Kapsamı: CLN un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: CLN şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Celon Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans

We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow

We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth

Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly

Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Recent updates

Second quarter 2024 earnings released: zł0.15 loss per share (vs zł0.18 profit in 2Q 2023)

A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price

New minor risk - Shareholder dilution

Price target increased by 26% to zł21.10

Celon Pharma S.A. Announces Strong Proof-Of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Oral Antipsychotic

Now 67% overvalued after recent price rise

Upcoming dividend of zł0.08 per share

Celon Pharma Announces Results of Phase Ii Clinical Trial for Cpl’ 116, A Jak/Rock Dual Inhibitor in the Treatment of Rheumatoid Arthritis (Ra)

Now 21% overvalued

Full year 2023 earnings released: zł0.55 loss per share (vs zł0.77 loss in FY 2022)

Consensus estimates of losses per share improve by 50%

Celon Pharma S.A. to Report Fiscal Year 2023 Results on Apr 24, 2024

Third quarter 2023 earnings released

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released

Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans

Upcoming dividend of zł0.09 per share at 0.6% yield

Full year 2022 earnings released

Celon Pharma S.A. to Report Q3, 2023 Results on Nov 22, 2023

Third quarter 2022 earnings released

Price target decreased to zł27.55

We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow

Price target decreased to zł27.55

Price target decreased to zł29.32

Second quarter 2022 earnings released

We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth

Consensus EPS estimates fall by 27%

Upcoming dividend of zł0.29 per share

Price target decreased to zł32.32

Consensus forecasts updated

Celon Pharma S.A., Annual General Meeting, Jun 22, 2022

Price target decreased to zł36.12

Consensus EPS estimates fall by 36%

Price target decreased to zł40.72

Price target decreased to zł43.23

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to zł45.23

Price target decreased to zł48.23

Second quarter 2021 earnings released: EPS zł0.01 (vs zł0.25 in 2Q 2020)

Upcoming dividend of zł0.07 per share

Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes

Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly

Price target increased to zł54.07

Celon Pharma Terminates Cooperation with Lupin Atlantis Holdings

Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)

Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor

Price target raised to zł50.30

Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Celon Pharma S.A. to Report Fiscal Year 2020 Results on Mar 31, 2021

Celon Pharma S.A. to Report Q1, 2021 Results on May 31, 2021

Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

Investor sentiment improved over the past week

New 90-day high: zł43.45

Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain

Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Third quarter 2020 earnings released: EPS zł0.088

Market bids up stock over the past week

New 90-day low: zł38.25

First half earnings released

New 90-day high - zł44.25

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin